Suptavumab

Drug Profile

Suptavumab

Alternative Names: REGN-2222; SAR-438584

Latest Information Update: 18 Nov 2016

Price : $50

At a glance

  • Originator Regeneron Pharmaceuticals
  • Class Monoclonal antibodies
  • Mechanism of Action Viral fusion protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Respiratory syncytial virus infections

Most Recent Events

  • 01 Sep 2016 Regeneron Pharmaceuticals completes a phase I trial in Healthy volunteers in USA (IM) (NCT02828397)
  • 01 Apr 2016 Regeneron Pharmaceuticals initiates a phase I trial in Healthy volunteers in USA (IM) (NCT02828397)
  • 29 Mar 2016 Phase-III clinical trials in Respiratory syncytial virus infections (Prevention, In infants, In neonates) in USA, Bulgaria, Denmark, Finland, Hungary, Netherlands, Puerto Rico, Spain, Sweden and United Kingdom (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top